

NEVRO CORP  
Form 8-K  
December 09, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 9, 2016**

**NEVRO CORP.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-36715**  
**(Commission**

**File Number)**  
**1800 Bridge Parkway**

**56-2568057**  
**(IRS Employer**

**Identification Number)**

Edgar Filing: NEVRO CORP - Form 8-K

**Redwood City, CA 94065**

**(Address of principal executive offices, including Zip Code)**

**Registrant's telephone number, including area code: (650) 251-0005**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On December 9, 2016, Nevro Corp. ( Nevro ) announced that Boston Scientific Corp. and Boston Scientific Neuromodulation Corp. (collectively, Boston Scientific ) have filed a patent infringement lawsuit alleging Nevro s manufacture, use and sale of the Senza® system infringes certain of Boston Scientific s patents covering technology related to stimulation leads, batteries and telemetry units. The lawsuit, filed in the United States District Court for the District of Delaware, seeks unspecified damages and attorney s fees, as well as preliminary and permanent injunctive relief against further infringement.

On November 28, 2016, Nevro filed a patent lawsuit against Boston Scientific asserting Boston Scientific infringes Nevro s patents covering its groundbreaking Senza® system and HF10 therapy.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NEVRO CORP.**

Date: December 9, 2016

By: /s/ Andrew H. Galligan  
Andrew H. Galligan  
Chief Financial Officer